These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1456384)

  • 21. Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous ("controlled release") administration in a model of generalized seizures in rats.
    Löscher W; Hönack D
    Epilepsia; 1995 Sep; 36(9):929-37. PubMed ID: 7649133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful initiation of combined therapy with valproate sodium injection and divalproex sodium extended-release tablets in the epilepsy monitoring unit.
    Boggs JG; Preis K
    Epilepsia; 2005 Jun; 46(6):949-51. PubMed ID: 15946337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multivariable analysis of factors governing the steady-state pharmacokinetics of valproic acid in 52 young epileptics.
    Hall K; Otten N; Johnston B; Irvine-Meek J; Leroux M; Seshia S
    J Clin Pharmacol; 1985; 25(4):261-8. PubMed ID: 3924980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative study of preparations of sodium and magnesium valproate (VPA) in treatment of patients with epileptic seizures].
    Onofrj M; Colangelo U; Malatesta G; Di Giovanni M
    Riv Neurol; 1988; 58(6):223-30. PubMed ID: 3150126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release divalproex in child and adolescent outpatients with epilepsy.
    Kernitsky L; O'Hara KA; Jiang P; Pellock JM
    Epilepsia; 2005 Mar; 46(3):440-3. PubMed ID: 15730542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy.
    Suzuki Y; Itoh H; Abe T; Nishimura F; Sato Y; Takeyama M
    J Pharm Pharmacol; 2011 Jul; 63(7):976-81. PubMed ID: 21635265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication.
    May T; Rambeck B
    Ther Drug Monit; 1990 Mar; 12(2):124-8. PubMed ID: 2107607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time-dependent interaction between phenytoin and valproic acid.
    Riva R; Albani F; Contin M; Perucca E; Ambrosetto G; Gobbi G; Santucci M; Procaccianti G; Baruzzi A
    Neurology; 1985 Apr; 35(4):510-5. PubMed ID: 3920548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy.
    Rosenfeld WE; Liao S; Kramer LD; Anderson G; Palmer M; Levy RH; Nayak RK
    Epilepsia; 1997 Mar; 38(3):324-33. PubMed ID: 9070595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old].
    Motte J; Pedespan JM; Sevestre M; Chiron C;
    Arch Pediatr; 2005 Oct; 12(10):1533-9. PubMed ID: 16099147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical usefulness of pediatric population parameter of slow-releasing preparation of sodium valproate].
    Yasuda K; Sugita K; Nakasa H; Niimi H
    No To Hattatsu; 1995 Jul; 27(4):282-5. PubMed ID: 7612288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study.
    Coppola G; Auricchio G; Federico R; Carotenuto M; Pascotto A
    Epilepsia; 2004 Sep; 45(9):1049-53. PubMed ID: 15329068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC; Dutta S
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproic acid efficacy, toxicity, and pharmacokinetics in neonates with intractable seizures.
    Gal P; Oles KS; Gilman JT; Weaver R
    Neurology; 1988 Mar; 38(3):467-71. PubMed ID: 3126410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate.
    Rinnerthaler M; Luef G; Mueller J; Seppi K; Wissel J; Trinka E; Bauer G; Poewe W
    Epilepsia; 2005 Feb; 46(2):320-3. PubMed ID: 15679514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.
    Kanner AM; Frey M
    Neurology; 2000 Aug; 55(4):588-91. PubMed ID: 10953201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of intractable childhood epilepsy with high-dose valproate.
    Ohtsuka Y; Amano R; Mizukawa M; Oka E; Ohtahara S
    Epilepsia; 1992; 33(1):158-64. PubMed ID: 1733751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of delayed and/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician.
    Dutta S; Reed RC
    J Clin Pharm Ther; 2006 Aug; 31(4):321-9. PubMed ID: 16882100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A single daily dose with valproic acid. A pharmacodynamic and clinical study].
    Pelzl G; Mamoli B
    Wien Klin Wochenschr; 1992; 104(10):286-9. PubMed ID: 1604872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluctuating and constant valproate administration gives equivalent seizure control in rats with genetic and acquired epilepsy.
    Dedeurwaerdere S; van Raay L; Morris MJ; Reed RC; Hogan RE; O'Brien TJ
    Seizure; 2011 Jan; 20(1):72-9. PubMed ID: 21093310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.